Arginine depletion as a therapeutic approach for patients with COVID-19
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a source of significant morbidity and death worldwide, and effective treatments are urgently needed. Clinical trials have focused largely on direct antiviral therapies or on immunomodulation in patients...
Main Authors: | Joseph M. Grimes, Shaheer Khan, Mark Badeaux, Ravi M. Rao, Scott W. Rowlinson, Richard D. Carvajal |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971220323043 |
Similar Items
-
Arginine enzymatic deprivation and diet restriction for cancer treatment
by: Wissam Zam
Published: (2017-10-01) -
A SARS-CoV-2 host infection model network based on genomic human Transcription Factors (TFs) depletion
by: Massimiliano Chetta, et al.
Published: (2020-10-01) -
Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
by: Johann Sellner, et al.
Published: (2021-01-01) -
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
by: Alessandra D’Abramo, et al.
Published: (2021-06-01) -
Arginine-Depleting Enzymes – An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies
by: Christin Riess, et al.
Published: (2018-11-01)